Beyond ICER: Arnold Foundation Wants To Dig Deeper On R&D And Pricing
Executive Summary
Arnold Foundation VP Mark Miller explains how research into “what it costs to bring a drug to market” could supplement existing efforts to determine how prescription drug prices line up with value.
You may also be interested in...
Arnold Ventures: How A Philanthropy Helped Tip The Scales In US Drug Pricing Debate
A review of grants by the organization to a range of recipients engaged in work on lowering drug prices.
Drug Pricing Legislation In The US May Be Losing Momentum
House subcommittee hearing on drug price negotiation bill championed by Speaker Nancy Pelosi showcases strong Republican opposition, and Senate Finance Committee Chairman Chuck Grassley suggests his bill may not be ready for a floor vote until next year.
As Washington Waits On Pricing Proposals, A Call For A Reset In R&D Debate
Policymakers should clarify link between high drug prices and innovation and figure out how to “rebalance” high prices with non-price innovation incentives before proceeding with policies aimed directly at lowering prices, Conti and David propose in the Health Affairs Blog.